



**PRESS RELEASE**

**EDEN BIODESIGN SIGNS MARKETING SERVICES AGREEMENT WITH  
HUMAN GENOME SCIENCES**

**New alliance will increase Human Genome Sciences' global marketing reach for large scale cGMP manufacturing services and provides a seamless range of services for clients from process development to 20,000L scale production**

**Liverpool, UK and Research Triangle Park, NC, USA; 13 August 2008:** Eden Biodesign Ltd., an expert provider of biopharmaceutical process development and cGMP manufacturing services today announced that they have entered into a marketing services agreement with Human Genome Sciences, Inc. (Nasdaq: HGSI, Rockville, MD).

Under the terms of the agreement, Eden Biodesign will use its expertise and global presence in the biopharmaceutical contract manufacturing market to assist HGS in identifying new manufacturing clients for their large scale commercial cell culture production facilities located in Rockville, MD. Both companies will use their combined expertise in process development, process scale-up, technology transfer, analytical and international regulatory support for biopharmaceuticals to provide customers with rapid and cost-effective transition into cGMP manufacturing at scales up to 20,000L and seamless access to commercial production capacity for biopharmaceuticals derived from mammalian cell culture.

“This alliance is particularly significant for Eden Biodesign and we are delighted that such a prestigious company as Human Genome Sciences has recognized Eden Biodesign’s technical excellence, global marketing reach and strong track record” commented Dr. Crawford Brown, Chief Executive Officer of Eden Biodesign. “In addition to our process development and clinical scale cGMP production services, our growing portfolio of successful clients may now also have seamless access to Human Genome Science’s world leading expertise in late-stage process development and state-of-the-art large scale production facilities as their products progress towards and into commercial launch”.

Eden Biodesign provides clients with a wide range of process development and cGMP manufacturing services for all major product categories from EMEA inspected facilities in Liverpool, UK. The company’s consulting arm offers global CMC support, cGMP training and a range of support services designed to accelerate clinical development and product launch.



Curran Simpson, Senior Vice President of Operations, HGS, said: “Eden Biodesign’s international business development presence and biopharmaceutical manufacturing expertise make them a partner of choice. Eden shares our commitment to technical excellence and brings considerable international regulatory experience and a proven history in biopharmaceutical development to our relationship”.

## **Ends**

For further information contact:

Media enquiries:

Liz Wyatt, De Facto Communications Ltd  
+44 (0)20 7861 3838  
Email [l.wyatt@defacto.com](mailto:l.wyatt@defacto.com)

Business enquiries:

Roger Lias, Ph.D., Group Commercial Director, Eden Biodesign  
(919) 349-2770  
Email [roger.lias@edenbiodesign.com](mailto:roger.lias@edenbiodesign.com)

## **Notes to editors:**

### **Eden Biodesign**

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides ‘state of the art’ development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of ‘Good Science’ at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit [www.edenbiodesign.com](http://www.edenbiodesign.com).

### **Human Genome Sciences**

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis



C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon® (albinterferon alfa-2b) for hepatitis C and LymphoStat-B® (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. More information about HGS is available on the HGS web site at [www.hgsi.com](http://www.hgsi.com).